Michael Tesar

1.7k total citations
36 papers, 1.4k citations indexed

About

Michael Tesar is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Michael Tesar has authored 36 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Radiology, Nuclear Medicine and Imaging, 18 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Michael Tesar's work include Monoclonal and Polyclonal Antibodies Research (20 papers), CAR-T cell therapy research (10 papers) and Viral Infections and Immunology Research (7 papers). Michael Tesar is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (20 papers), CAR-T cell therapy research (10 papers) and Viral Infections and Immunology Research (7 papers). Michael Tesar collaborates with scholars based in Germany, United States and France. Michael Tesar's co-authors include Otfried Marquardt, Wolf‐Rainer Abraham, Edward R. B. Moore, Kenneth N. Timmis, Donald F. Summers, Ellie Ehrenfeld, Oliver Pelz, Antoni Bennasar-Figueras, Peter Lowe and Sven Berger and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Tesar

35 papers receiving 1.3k citations

Peers

Countries citing papers authored by Michael Tesar

Since Specialization

Citations

This map shows the geographic impact of Michael Tesar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Tesar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Tesar more than expected).

Fields of papers citing papers by Michael Tesar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Tesar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Tesar. The network helps show where Michael Tesar may publish in the future.

Co-authorship network of co-authors of Michael Tesar

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Tesar. A scholar is included among the top collaborators of Michael Tesar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Tesar. Michael Tesar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method 2023 ·mAbs ·Thomas Müller, (unknown), Michael Tesar, Ivica Fucek, (unknown), Joachim Koch, Kristina Ellwanger	5
2	Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers 2022 ·Antibodies ·Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Thomas Müller, (unknown), Joachim Koch, Michael Tesar	9
3	Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies 2017 ·Frontiers in Oncology ·Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Stefan Knackmuss, Michael Weichel, Thorsten Gantke, (unknown), Eugene A. Zhukovsky, Michael Tesar, Martin Treder	25
4	Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy 2017 ·Transfusion Medicine and Hemotherapy ·Joachim Koch, Michael Tesar	18
5	NanoLuc Luciferase – A Multifunctional Tool for High Throughput Antibody Screening 2016 ·Frontiers in Pharmacology ·Nicolas Boute, Peter Lowe, Sven Berger, Martine Malissard, Alain Robert, Michael Tesar	54
6	Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells 2002 ·Nature Medicine ·Zoltan A. Nagy, Bernd Hubner, (unknown), Robert Rauchenberger, Silke U. Reiffert, (unknown), Stefan Zahn, (unknown), (unknown), (unknown), Christoph Brunner, (unknown), Benno Rattel, Michael Stanglmaier, Michael Hallek, Mark Wing, Steven W. Anderson, Matt Dunn, Titus Kretzschmar, Michael Tesar	122
7	High-throughput generation and engineering of recombinant human antibodies 2001 ·Journal of Immunological Methods ·Barbara Krebs, Robert Rauchenberger, Silke U. Reiffert, Christine Rothe, Michael Tesar, Elisabeth Thomassen, Manqiu Cao, Torsten Dreier, David Fischer, A. Höss, Landon J. Inge, Achim Knappik, Matthias Marget, Peter Pack, (unknown), Robert Schier, P. Söhlemann, Jill Winter, Joachim Wölle, Titus Kretzschmar	130
8	Anti‐VEGFR‐2 scFvs for Cell Isolation. Single‐Chain Antibodies Recognizing the Human Vascular Endothelial Growth Factor Receptor‐2 (VEGFR‐2/flk‐1) on the Surface of Primary Endothelial Cells and Preselected CD34 ⁺ Cells from Cord Blood 2001 ·Stem Cells ·Thomas Böldicke, Michael Tesar, (unknown), (unknown), Hermann‐Josef Gröne, Johannes Waltenberger, Órit Kollet, Tsvee Lapidot, Avner Yayon, Herbert A. Weich	37
9	Bypassing hybridoma technology: HLA‐C reactive human single‐chain antibody fragments (scFv) derived from a synthetic phage display library (HuCAL) and their potential to discriminate HLA class I specificities 2000 ·Tissue Antigens ·Matthias Marget, Bhavya Bhavna Sharma, Michael Tesar, Titus Kretzschmar, Stefan Jenisch, E. Westphal, (unknown), Étienne Weiss, Matthias Ulbrecht, Dieter Kabelitz, Martin Krönke	9
10	Towards elucidation of microbial community metabolic pathways: unravelling the network of carbon sharing in a pollutant‐degrading bacterial consortium by immunocapture and isotopic ratio mass spectrometry 1999 ·Environmental Microbiology ·Oliver Pelz, Michael Tesar, Rolf‐Michael Wittich, Edward R. B. Moore, Kenneth N. Timmis, Wolf‐Rainer Abraham	119
11	Multifunctional g3p-peptide tag for current phage display systems 1998 ·Journal of Immunological Methods ·Christiane Beckmann, (unknown), Kenneth N. Timmis, Michael Tesar	12
12	Monitoring of scFv selected by phage display using detection of scFv–pIII fusion proteins in a microtiter scale assay 1998 ·Journal of Immunological Methods ·(unknown), Alexej Schmidt, Michael Tesar, (unknown), Martin Welschof, (unknown), Peter Terness, Melvyn Little, Klaus Pfizenmaier, Dieter Moosmayer	19
13	Replication of hepatitis A viruses with chimeric 5' nontranslated regions 1996 ·Journal of Virology ·Xiaoteng Jia, Michael Tesar, Donald F. Summers, Ellie Ehrenfeld	17
14	Monoclonal antibody against pIII of filamentous phage: an immunological tool to study pIII fusion protein expression in phage display systems 1995 ·Immunotechnology ·Michael Tesar, Christiane Beckmann, (unknown), (unknown), (unknown), Kenneth N. Timmis	31
15	Expression of Hepatitis A Virus Precursor Protein P3 in Vivo and in Vitro: Polyprotein Processing of the 3CD Cleavage Site 1994 ·Virology ·Michael Tesar, (unknown), Xi-Yu Jia, Oliver C. Richards, Donald F. Summers, Ellie Ehrenfeld	27
16	Analysis of a Potential Myristoylation Site in Hepatitis A Virus Capsid Protein VP4 1993 ·Virology ·Michael Tesar, Xi-Yu Jia, Donald F. Summers, (unknown)	36
17	Hepatitis A virus polyprotein synthesis initiates from two alternative AUG codons 1992 ·Virology ·Michael Tesar, Shirley A. Harmon, Donald F. Summers, Ellie Ehrenfeld	39
18	Foot-and-mouth disease virus protease 3C inhibits cellular transcription and mediates cleavage of histone H3 1990 ·Virology ·Michael Tesar, Otfried Marquardt	61
19	Identification of foot-and-mouth disease virus replication in vaccinated cattle by antibodies to non-structural virus proteins 1990 ·Vaccine ·(unknown), O. C. Straub, R. Ahl, Michael Tesar, Otfried Marquardt	71
20	Serological probes for some foot-and-mouth disease virus nonstructural proteins 1989 ·Virus Genes ·Michael Tesar, (unknown), Otfried Marquardt	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact